1. Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials
- Author
-
Liu, Anthony PY, Gudenas, Brian, Lin, Tong, Orr, Brent A, Klimo, Paul, Kumar, Rahul, Bouffet, Eric, Gururangan, Sridharan, Crawford, John R, Kellie, Stewart J, Chintagumpala, Murali, Fisher, Michael J, Bowers, Daniel C, Hassall, Tim, Indelicato, Daniel J, Onar-Thomas, Arzu, Ellison, David W, Boop, Frederick A, Merchant, Thomas E, Robinson, Giles W, Northcott, Paul A, and Gajjar, Amar
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Pediatric Cancer ,Genetics ,Clinical Trials and Supportive Activities ,Biotechnology ,Pediatric ,Clinical Research ,Prevention ,Cancer ,Adolescent ,Age Factors ,Brain Neoplasms ,Child ,Child ,Preschool ,Cohort Studies ,DNA Methylation ,Female ,Humans ,Male ,Pineal Gland ,Pinealoma ,Proto-Oncogene Mas ,Risk Factors ,Survival Rate ,Young Adult ,Pineoblastoma ,Clinical trial ,Molecular subgroups ,DICER1 ,MicroRNA processing ,FOXR2 ,Neurosciences ,Neurology & Neurosurgery - Abstract
Pineoblastoma is a rare embryonal tumor of childhood that is conventionally treated with high-dose craniospinal irradiation (CSI). Multi-dimensional molecular evaluation of pineoblastoma and associated intertumoral heterogeneity is lacking. Herein, we report outcomes and molecular features of children with pineoblastoma from two multi-center, risk-adapted trials (SJMB03 for patients ≥ 3 years; SJYC07 for patients
- Published
- 2020